C07K 16/241
Tumor necrosis factors
Official title: {Tumor Necrosis Factors}
C07K16/241 (Tumor necrosis factors) appears on 1,420 US grants and 2,682 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,420
- Published applications
- 2,682
- Assignees
- 763
- Inventors
- 3,399
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 20 | 0 |
| 1998 | 10 | 0 |
| 1999 | 22 | 0 |
| 2000 | 11 | 0 |
| 2001 | 19 | 13 |
| 2002 | 22 | 37 |
| 2003 | 25 | 88 |
| 2004 | 11 | 56 |
| 2005 | 8 | 46 |
| 2006 | 23 | 90 |
| 2007 | 38 | 61 |
| 2008 | 23 | 69 |
| 2009 | 29 | 96 |
| 2010 | 34 | 86 |
| 2011 | 36 | 77 |
| 2012 | 51 | 96 |
| 2013 | 54 | 121 |
| 2014 | 78 | 161 |
| 2015 | 97 | 187 |
| 2016 | 114 | 178 |
| 2017 | 82 | 155 |
| 2018 | 61 | 111 |
| 2019 | 74 | 147 |
| 2020 | 95 | 128 |
| 2021 | 82 | 153 |
| 2022 | 70 | 118 |
| 2023 | 62 | 125 |
| 2024 | 63 | 113 |
| 2025 | 58 | 100 |
| 2026 | 34 | 70 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Hydrophilic linkers for antibody or DARPin conjugates8 Sep 2026US 12,729,236 B2Valitor, Inc.
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- Composition for cancer diagnosis18 Aug 2026US 12,710,425 B2Acurasysbio Co., Ltd.
- Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof11 Aug 2026US 12,703,742 B2
- Bacterial hosts for recombinant protein expression7 Jul 2026US 12,674,172 B2Pelican Technology Holdings, Inc.
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha8 Oct 2026US 2026/0308243 A1Janssen Biotech, Inc.
- Treatment of autoimmune diseases8 Oct 2026US 2026/0308244 A1UCB Developed Brands SRL
- Manufacturing methods for producing anti-tnf antibody compositions1 Oct 2026US 2026/0297173 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Production of chimeric antibodies - a combinatorial approach1,367US 5,565,332 ACambridge Antibody Technology Limited · 1996
- Humanised antibodies1,093US 5,859,205 ACelltech Limited · 1999
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Human antibodies derived from immunized xenomice1,057US 6,075,181 AAbgenix, Inc. · 2000
- Human antibodies derived from immunized xenomice943US 6,150,584 AAbgenix, Inc. · 2000